Email this page: News Release
VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by VIVUS, Inc. for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps VIVUS, Inc. prevent automated submissions.